Top Suppliers:I want be here
Related CAS#:
54910-89-3 114798-39-9
100568-02-3 59333-67-4
56296-78-7 100568-03-4
57226-07-0 71258-22-5
651316-65-3 114414-02-7
1158522-08-7 30748-93-7
1188184-23-7 940364-43-2
134104-43-1 131615-57-1
6906-52-1 1783775-27-8
930439-75-1 1018584-77-4

54910-89-3

54910-89-3 structure
54910-89-3 structure
  • Name: Fluoxetine
  • Chemical Name: Fluoxetine
  • CAS Number: 54910-89-3
  • Molecular Formula: C17H18F3NO
  • Molecular Weight: 309.326
  • Catalog: API Nervous system medication Antidepressant, manic
  • Create Date: 2018-02-05 08:00:00
  • Modify Date: 2024-01-02 17:11:26
  • Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.
Name Fluoxetine
Synonyms Adofen
MFCD00072041
AURORA KA-7692
Reneuron
Fluctin
Foxetin
Fluoxeren
Fluval
fluoxetina
EINECS 611-209-7
Description Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.
Related Catalog
In Vitro Fluoxetine blocks the downregulation of cell proliferation resulting from inescapable shock (IS) of hippocampal cell[1]. Fluoxetine increases the number of newborn cells in the dentate gyrus of the hippocampus of adult rat. Fluoxetine also increases the number of proliferating cells in the prelimbic cortex[2]. Fluoxetine accelerates the maturation of immature neurons. Fluoxetine enhances neurogenesis-dependent long-term potentiation (LTP) in the dentate gyrus[3]. Fluoxetine, but not citalopram, fluvoxamine, paroxetine and sertraline, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Fluoxetine produces robust and sustained increases in extracellular concentrations of norepinephrine and dopamine after acute systemic administration[4].
In Vivo Fluoxetine treatment also reverses the deficit in escape latency observed in animals exposed to inescapable shock in adult male Sprague-Dawley rats[1]. Fluoxetine (5 mg/kg) alone increases cell proliferation in the dentate gyrus. Coadministration (fluoxetine 5 mg/kg + olanzapine) also significantly increases the number of BrdU-positive cells compared with the control group[2]. Fluoxetine combined with Olanzapine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline, respectively, which are significantly greater than either drug alone[5].
Animal Admin Male Sprague-Dawley rats weighing 250-300 g are housed under a 12-hour light/12-hour dark cycle (lights on at 7:00 am, lights off at 7:00 pm) and at constant temperature (25°C) and humidity and allowed free access to food and water. For chronic drug treatments, rats are administered fluoxetine (5 mg/kg/day) or saline by intraperitoneal (IP) injection once daily and olanzapine or vehicle in the drinking water for 21 days (vehicle-treated control, fluoxetine, and olanzapine alone) plus the combination of fluoxetine and olanzapine. For combination treatment, olanzapine is chosen because fluoxetine is known to interfere with the metabolism of olanzapine and raise the blood levels by up to 4-6 times. Olanzapine is dissolved in hydrochloric acid (HCl), then adjusted back to pH 6 with 1 N sodium hydroxide to make the stock solution of 3 mg/mL concentration. The same amount of vehicle solution is added to the water for the control animals. Fluid intake is measured three times per week, and drinking bottles are replenwashed with fresh drug solution. There are no differences in fluid intake among the treatment groups. For subchronic treatment, drugs are administered exactly the same way but for a total period of 7 days.
References

[1]. Malberg JE, et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003 Sep;28(9):1562-71

[2]. Kodama M, et al. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004 Oct 15;56(8):570-80.

[3]. Wang JW, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008 Feb 6;28(6):1374-84.

[4]. Bymaster FP, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002 Apr;160(4):353-61

[5]. Zhang W, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep;23(3):250-62.

[6]. Avitsur R1. Increased symptoms of illness following prenatal stress: Can it be prevented by fluoxetine? Behav Brain Res. 2017 Jan 15;317:62-70.
Density 1.2±0.1 g/cm3
Boiling Point 395.1±42.0 °C at 760 mmHg
Melting Point 158ºC
Molecular Formula C17H18F3NO
Molecular Weight 309.326
Flash Point 192.8±27.9 °C
Exact Mass 309.134064
PSA 21.26000
LogP 4.09
Vapour Pressure 0.0±0.9 mmHg at 25°C
Index of Refraction 1.511

CHEMICAL IDENTIFICATION

RTECS NUMBER :
DA8326855
CHEMICAL NAME :
Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-
CAS REGISTRY NUMBER :
54910-89-3
LAST UPDATED :
199801
DATA ITEMS CITED :
9
MOLECULAR FORMULA :
C17-H18-F3-N-O
MOLECULAR WEIGHT :
309.36

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
60 mg/kg/21W-I
TOXIC EFFECTS :
Nutritional and Gross Metabolic - other changes
REFERENCE :
AJPSAO American Journal of Psychiatry. (American Psychiatric Assoc., Circulation Dept., 1400 K St., NW, Washington, DC 20005) V.78- 1921- Volume(issue)/page/year: 153,134,1996
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
72 mg/kg/26W-I
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
REFERENCE :
JCPYDR Journal of Clinical Pyschopharmacology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1981- Volume(issue)/page/year: 10,343,1990
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
16800 ug/kg/6W-I
TOXIC EFFECTS :
Behavioral - muscle weakness Behavioral - antipsychotic Nutritional and Gross Metabolic - other changes
REFERENCE :
AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908- Volume(issue)/page/year: 156,681,1996
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
2 mg/kg/5D-I
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - other changes
REFERENCE :
AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908- Volume(issue)/page/year: 156,681,1996
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
825 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 15,1178,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
121 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 15,1178,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
464 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 15,1178,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
87500 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 15,1178,1990 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
80 mg/kg
SEX/DURATION :
female 13-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic
REFERENCE :
JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 280,138,1997
Hazard Codes C,Xi
Risk Phrases R34:Causes burns. R36/37:Irritating to eyes and respiratory system . R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Phrases S23-S26-S27-S36/37/39-S45-S37/39
RIDADR UN 3265 8/PG 2
WGK Germany 2
Packaging Group III
Hazard Class 8
HS Code 29036990
HS Code 29036990

Chemsrc provides CAS#:54910-89-3 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 54910-89-3 | Chemsrc address: https://www.chemsrc.com/en/baike/390552.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved